Overview

Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma

Status:
Unknown status

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have recurrent or refractory acute leukemia, chronic myeloid leukemia, myelodysplasia, lymphoma, or myeloma.

Phase:

Phase 2

Details

Lead Sponsor:

Our Lady of Mercy Medical Center

Treatments:

Arsenic Trioxide